Better Therapeutics, Inc. (BTTX)
- Previous Close
0.0122 - Open
0.0150 - Bid 0.0360 x 800
- Ask 0.0370 x 1400
- Day's Range
0.0080 - 0.0150 - 52 Week Range
0.0050 - 1.3500 - Volume
40,811 - Avg. Volume
5,620,893 - Market Cap (intraday)
812,282 - Beta (5Y Monthly) 2.07
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1000 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
www.bettertx.comRecent News: BTTX
Performance Overview: BTTX
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BTTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BTTX
Valuation Measures
Market Cap
664.00k
Enterprise Value
8.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-95.05%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.57M
Diluted EPS (ttm)
-1.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.56M
Research Analysis: BTTX
Company Insights: BTTX
BTTX does not have Company Insights